Bifunctional peptides with mucoadhesive and virus-binding properties

JP2025514630A5Pending Publication Date: 2026-04-14FREE UNIV OF BERLIN +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
FREE UNIV OF BERLIN
Filing Date
2023-03-31
Publication Date
2026-04-14

AI Technical Summary

Technical Problem

Current measures for addressing viral diseases, such as SARS-CoV-2, are limited by the slow development of vaccines and the emergence of resistance to antiviral drugs, necessitating the development of novel prophylactic treatments that can effectively prevent viral infection.

Method used

A bifunctional peptide with a virus binding site and a mucin binding site covalently linked, allowing for targeted binding to viral pathogens and mucins, thereby enhancing the innate barrier function of respiratory mucus and preventing viral infection.

Benefits of technology

The bifunctional peptide effectively captures and removes viral pathogens from the respiratory mucosa, reducing the risk of infection and disease, while also having potential therapeutic applications in infected patients by reducing viral titers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides novel substances that are useful for the preventive treatment of viral diseases, and ideally, for avoiding viral infections. The bifunctional peptide of the present invention has a virus-binding site 2 and a mucin-binding site 1 covalently linked to the virus-binding site 2. The virus-binding site 2 is selected from peptides that bind to SARS-CoV-2, influenza A, influenza B, rhinovirus, or other enteroviruses, human parainfluenza viruses, and / or metaneuviruses. The mucin-binding site 1 is selected from lectins such as trefoil factor 3.
Need to check novelty before this filing date? Find Prior Art